SF
ELDN icon

Summit Financial’s Eledon Pharmaceuticals ELDN Stock Holding History

Summit Financial’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.3K Hold
11,500
– – ﹤0.01% 1575
2026
Q1 		$35.4K Hold
11,500
– – ﹤0.01% 1396
2025
Q4 		$17.4K Hold
11,500
– – ﹤0.01% 1283
2025
Q3 		$29.8K Buy
+11,500
New +$33.6K ﹤0.01% 1234

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Summit Financial's ELDN Position: Q2 2026 in Review

Summit Financial held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 11,500 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1575.

Summit Financial first reported a position in ELDN in Q3 2025 and has held it in 4 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Summit Financial held 11,500 shares of Eledon Pharmaceuticals worth $45.3K as of Q2 2026.
  • Summit Financial left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Summit Financial's portfolio in Q2 2026, its #1575 holding.
  • Summit Financial first reported a position in Eledon Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.